Biomed Imaging Interv J 2007; 3(4):e10
doi: 10.2349/biij.3.4.e10
© 2007 Biomedical Imaging and
Intervention Journal
Learning Points
Low back pain
S Kunanayagam1,*, MRCP, Dip. Med. Elderly,
D Harichandra2, MD, MMed,
S Sargunan1, MBBS, MMed
1 Department of Medicine, Faculty of Medicine,
University of Malaya, Kuala Lumpur, Malaysia
2 Department of Biomedical Imaging, Faculty of Medicine, University
of Malaya, Kuala Lumpur, Malaysia
A 68-year-old woman presented to the orthopaedics clinic
with a 3-month history of low back pain. She was unable to recall any falls
recently but claimed to have first felt the pain when she tried to look for her
cat in the drain after it went missing. She had taken paracetamol regularly for
the pain. However, the pain persisted so she decided to see a doctor. There were
no other significant medical illnesses such as diabetes, hypertension or renal
impairment.
On physical examination, there were no positive findings
except for a mild kyphosis and tenderness over the thoraco-lumbar junction.
Plain radiographs of her spine and a Dual Energy X-ray Absorptiometry (DEXA)
study of her spine and femur were performed (Figures 1 and 2).

Questions:
1.
What is the most likely diagnosis?
2.
What is the differential diagnosis and how are they distinguished using
the imaging methods available?
3.
What are the limitations of the imaging method that is used to diagnose this
condition?
4.
This condition has obvious serious complications. What are the risk
factors and how are they currently managed?

Answers:
1. What is the most likely diagnosis?
On the plain radiographs of the spine, there is generalized
osteopenia with loss of the heights of the L1, L2, and L3 vertebral bodies with
preservation of the disc spaces (cod fish vertebra) (Figures 1a and 1b in the
answer). There are no associated soft tissue masses and the pedicles appear
intact. No evidence of any erosion of the ribs or pelvic bones. The loss of
heights of the vertebral spaces indicates an obvious compression fracture of
the L1, L2 and L3, which is most likely due to osteoporosis.
The DEXA of the spine (Figure 2a) shows the T scores for L1-L5 range from -1.9 to -2.8. The mean T-score of L2-L4 lumbar vertebra was -2.3. The DEXA of the hip (Figure 2b) shows femoral neck T-score of -3.0 and Total T-score of -2.4.
The higher bone mineral density values for L1 and L3 are related to the compression fractures. The L2 vertebra although having a lower bone mineral density appears collapsed in the plain film. Compression fractures give a higher bone mineral density values and consequently may increase the T score value. Thus, they are not reflective of the true density of the vertebra. In this case, the L4 lumbar vertebra with the T-score of -2.8 should be used as the reference vertebra.
These findings then would be consistent with severe (established) osteoporosis.
2. What is the differential diagnosis and how are they distinguished
using the imaging methods available?
The important differential diagnosis in this situation would
be:
1.
Pathological fractures due to metastatic lesions.
2.
Pathological fractures due to benign lesions.
Since most bony metastases are haematogeneous in origin, the
axial skeleton with its abundant vascularisation and red bone marrow, is the
most common site of skeletal metastases (39%) [1]. However, osteoporotic
compression fractures, which occur commonly, can be confused with metastatic
compression fracture in the acute phase. Since the prognosis and management
differs in these two entities, accurate diagnosis is important [2]. Although
metastases on plain radiographs are classically associated with soft tissue
masses and destruction of the pedicles, these findings have low sensitivity.
In today�s clinical environment, the specific discrimination
between benign and malignant vertebral compression fractures relies heavily on magnetic
resonance (MR) imaging features.
However, a confident diagnosis is not always possible in
routine MR sequences because signal changes can be similar [3]. Common
morphologic signs for assessing the cause of the fracture include the degree
and pattern of bone marrow replacement, multiplicity of lesions, para-vertebral
soft tissue masses and infiltration of posterior elements of the vertebra that
indicate metastatic lesions [4]. Benign vertebral fractures may have
enhancement after intravenous administration of contrast media due to breach in
blood tissue barrier [5]. When the findings on routine MR sequences are
inconclusive for the diagnosis of acute benign or malignant vertebral body
compression fracture, the use of diffusion weighted MR sequence is recommended
[6]. Malignant pathological fractures have high signal intensity compared to
normal bone marrow (Figure 4), while benign osteoporotic and traumatic
fractures are found to be low in signal intensity (Figure 3). Diffusion
weighted imaging (DWI) has a higher specificity (92%) in detecting malignant
vertebral compression fractures than the contrast enhanced MR images although
the usefulness and efficacy is still controversial [7]. However, in another
study it was found that absence of contrast enhancement had a high negative
predictive value (90%) while steady-state free-precession (SSFP) DWI had both a
high positive predictive value (90%) and high negative predictive value (90%)
in detecting malignant vertebral compression fractures. This study also found
that the ratio of lesion intensity technique offers another excellent criterion
to differentiate between benign and malignant lesions [8].
3. What are the limitations of the imaging method that is
used to diagnose this condition?
Osteoporosis is a skeletal disorder characterized by low
bone mass, microarchitectural disruption and increased skeletal fragility. The
presence of low bone mass is usually determined by radiologic testing. Plain
radiographs can demonstrate osteopenia.
Quantitative X-ray densitometry gives an accurate estimate
of bone mineral density (BMD) and is the method of choice.
The difference between the patient�s BMD and that of a
healthy young adult is referred to as a standard deviation (SD). As outlined in
the World Health Organization�s diagnostic categories, individuals whose
T-score is within one standard deviation of the �norm� are considered to have
normal bone density. Scores below the �norm� are indicated in negative numbers.
For example, a score from -1 to -2.5 SD below the norm indicates low bone mass,
or osteopenia, and a score of more than -2.5 SD below the norm is considered a
diagnosis of osteoporosis. For most BMD tests, -1 SD equals a 10 to 12%
decrease in bone density (Table 1). Since there are many more persons with
osteopenia than persons with osteoporosis, approximately half of fragility fractures
occur in the osteopenic group, although the relative risk of fracture is higher
in the osteoporotic population. An additional procedure called Lateral
Vertebral Assessment (LVA) (using the DEXA machine to obtain a lateral view of
the lumbosacral spine) may be used to screen for vertebral fractures. It may be
recommended for older patients, especially if they have lost more than an inch
of height, have unexplained back pain, or if the DEXA scan gives borderline
readings. The increased risk, if the patient has evidence of fracture, would
influence decisions with regards to treatment. The current recommendation is to
perform dual-energy X-ray absorptiometry of the lumbar vertebra (L1 to L4),
the hip [including the femoral neck, Ward�s triangle, the greater trochanter,
and the total hip (which includes all these measures)] or both (Figures 1 and
2). The results are presented visually, including both T scores and Z scores
(the bone density in the patient as compared with other people of the same age
and size expressed as the number of SDs above or below the mean). The BMD
measurements of the hip, femoral neck and total hip, in particular, are the
most useful in predicting fracture, whereas measurements of Ward�s triangle
show great variation and are of little clinical value. Although it has been
suggested that the WHO definition of osteoporosis should be reserved for
patients with low T scores for the total hip, low T scores at other sites are
also considered diagnostic of osteoporosis. Spinal measurements may be
particularly important in younger postmenopausal women, since they may show
osteoporotic values earlier than the hip measurements.
Z scores are more informative than T scores in young
persons, since the scoring allows comparison of bone density with persons of
similar age, height, and weight. Generally, a Z score of -2.0 or lower is
considered an indication of the need for more intensive evaluation of possible
secondary causes of bone loss, although such causes should be considered in all
cases. The decision to test for BMD should be based on an individual�s risk
profile, and testing is never indicated unless the results could influence a
treatment decision.
However, using DEXA as the gold standard has its limitations
especially in older women, where sclerotic changes that occur with age, largely
owing to osteoarthritis, may result in an artefactual increase in measured BMD.
The presence of vertebral compression fractures or osteoarthritis may interfere
with the accuracy of the test. CT scans may be more useful in such instances. A
careful examination of the actual DEXA printout may help resolve this issue.
However, in such instances, clinical history, a thorough re-assessment of the
patient�s risk factors and spinal radiographs will help in establishing a
diagnosis of osteoporosis.
The sites at which the DEXA measurements are taken (either
centrally or peripherally [pDEXA]) also have an important bearing on the
validity of the examination. Central DEXA devices are more sensitive than pDEXA
devices but they are also somewhat more expensive. The peripheral devices do
not accurately follow changes in bones during therapy. A pDEXA on heel or
wrist, may help predict the risk of fracture in the spine or hip but since bone
mass tends to vary from one location to the other, measuring the heel is not as
accurate as measuring the spine or hip. Small changes may normally be observed
between scans due to differences in positioning and may not be significant. BMD
measurement in the forearm bone is not used routinely but is recommended for
patients with primary hyperparathyroidism, since this site may show the
greatest bone loss. Most importantly, the examination must be done with great
care to maximise accuracy.
In addition, DEXA cannot predict who will experience fractures
but will indicate relative risk. BMD can also be measured by quantitative
computed tomography (QCT). This technique can analyze trabecular and cortical
bone separately and is a sensitive measure of early bone loss in the vertebra.
However, the application of T scores to predict the risk of fracture with the
use of quantitative CT has not been validated, and this technique is usually
more costly and results in greater exposure to radiation than does DEXA.
4. This condition has obvious serious complications. What
are the risk factors and how are they currently managed?
The National Osteoporosis Foundation (NOF) Physicians� Guide
to Prevention and Treatment of Osteoporosis [9] suggests BMD testing should be
performed on:
●
All women aged 65 and older regardless of risk factors.
●
Younger postmenopausal women with one or more risk factors (other than
being Caucasian, postmenopausal and female).
●
Postmenopausal women who present with fractures (to confirm the
diagnosis and determine disease severity).
The risk factors for this condition are listed in Table 2.
The most important risk factor for fracture, independent of BMD, is a previous
fragility fracture. Falls are another important predictor, particularly for hip
fractures in the elderly. Hence, factors that increase the risk of falling -
such as impaired vision, neuromuscular deficits, or medications that affect
balance - should also be assessed. Screening for osteoporosis should ideally
provide an estimate of the absolute risk of any fragility fracture during the
subsequent 5 or 10 years. Estimates of relative risk associated with various
factors differ among studies, but there is general consensus regarding the
importance of several key factors in risk assessment.
For example, the absolute 10-year risk of a fragility
fracture in a postmenopausal woman with a T score of -2.5 or less and no other
risk factors is less than 5 percent at the age of 50 but more than 20 percent
at the age of 65. Absolute risk increases further with additional risk factors,
particularly with a previous fragility fracture. In postmenopausal Caucasian
women, the relative risk of fracture is increased by a factor of 1.5 to 3 for
each decrease of 1.0 in the T score, depending on the site measured. The
relative risk increases by a factor of 2 to 3 per decade after the age of 50.
The risk increases by a factor of 1.2 to 2 for patients who have a family
history of fracture in a first-degree relative, who weigh less than 126 lb (57
kg), who have recently lost 10 lb or more of weight, who had a delayed menarche
(e.g., at an age of more than 15 years), or who currently smoke. These factors
are also associated with a greater likelihood of low BMD [10]. Osteoporosis has
no clinical manifestations until there is a fracture. One in two women and one
in four men over age 50 will have an osteoporosis-related fracture in her/his
remaining lifetime. Osteoporosis is responsible for more than 1.5 million
fractures annually. Vertebral fractures are the most important clinical
manifestation of osteoporosis. Successive crush fractures can lead to an
increased thoracic (dorsal) kyphosis with height loss and the development of �dowager�s
hump� [11].
Other fractures include hip fractures that are relatively
common affecting 15% of women and 5% of men by the age of 80. The rate of hip
fractures is two to three times higher in women than men; however, the one-year
mortality following a hip fracture is nearly twice as high for men as for
women. A woman�s risk of hip fracture is equal to her combined risk of breast,
uterine and ovarian cancer. An average of 24% of hip fracture patients aged 50
and over dies in the year following their fracture. One in five of those who
were ambulatory before their hip fracture required long-term care afterward. At
6 months after a hip fracture, only 15% of patients could walk across a room
unaided. Vertebral fractures are also linked with an increased risk of death.
In addition, distal radial fractures (Colles� fractures) may occur.
Prevention and treatment of osteoporosis consists of non-pharmacological,
pharmacological or hormonal therapy.
Pharmacologic therapy
Among the antiresorptive therapies, bisphosphonates such as
alendronate and risedronate have demonstrated consistent efficacy in reducing
vertebral and non-vertebral fracture risk. Once-weekly alendronate and
risedronate produced similar improvements in BMD compared with their once-daily
counterparts with similar tolerability. Daily injections of teriparatide
resulted in statistically significant reductions in the risk of vertebral and
non-vertebral fractures. Trials of ibandronate, raloxifene and calcitonin nasal
spray showed reductions in vertebral fracture risk. Hormone therapy has
demonstrated clinical fracture risk reduction; however, safety outcomes from
the Women�s Health Initiative study have raised concerns regarding long-term
use of these preparations [12].
Non-pharmacological therapy
Non-pharmacologic therapy consists of three components:
1.
Diet: an optimal intake of calories is needed to prevent malnutrition.
Post menopausal women and older men (above 65 years old) should take an
adequate amount of elemental calcium i.e. 500-1000 mg/day [13] and vitamin D.
Women should ingest approximately 800 IU vitamin D per day with higher doses
required for those with malabsorption and patients on concomitant
anticonvulsant therapy.
2.
Exercise: women with osteoporosis or those aiming to prevent it should
exercise for at least 30 minutes three times per week. Exercise has been
associated with an improvement in BMD and decreased risk of hip fractures in
women [14].
3.
Cessation of smoking: Smoking one pack per day throughout adult life is
associated with a 5 to 10% reduction in bone density [15].

Discussion
The case discussed illustrates the importance of considering
the diagnosis of osteoporosis in a patient with low back pain. As shown in the
answer to question 1, plain radiographs of the spine are often sufficient to
make a diagnosis of osteoporosis, hence treatment can be initiated. This is a
readily available imaging method.
Question 2 addresses the importance of the differential
diagnosis, in this case a metastatic compression fracture. Treatment and
approach will be different; hence an MRI will be important when the clinical
suspicion is high. DWI MRI can give a clearer picture to the clinical scenario
when the physician needs to differentiate between an osteoporotic and a
malignant fracture.
BMD is a popular method used to diagnose osteoporosis. It is
a screening test, which is not without its limitations. The decision to subject
a patient to a DEXA scan is based upon a set of criteria while the decision to treat
osteoporosis is based on a careful study of the patient�s BMD.
The risk factor for a new osteoporotic fracture is a
previous fragility fracture. It is important to note that falls need to be
prevented in the first place. Untreated fractures can lead to significant
immobility in the elderly which predispose them to the need for long-term
care. Bisphosphonates such as alendronate and risedronate have shown good
efficacy in reducing vertebral and non-vertebral fracture risk. Other drugs
such as teriparatide (daily injections of synthetic parathyroid hormone) have
also been similarly effective.
REFERENCES
-
Porter BA, Smith JP, Stimac GK. Magnetic resonance imaging for marrow-infiltrating neoplasms. West J Med 1992; 156(4):437.
[Medline]
-
Falcone S. Diffusion-weighted imaging in the distinction of benign from metastatic vertebral compression fractures: is this a numbers game? AJNR Am J Neuroradiol 2002; 23(1):5-6.
[Medline]
-
Tan SB, Kozak JA, Mawad ME. The limitations of magnetic resonance imaging in the diagnosis of pathologic vertebral fractures. Spine 1991; 16(8):919-23.
[Medline]
-
Baur A, Stabler A, Arbogast S et al. Acute osteoporotic and neoplastic vertebral compression fractures: fluid sign at MR imaging. Radiology 2002; 225(3):730-5.
[Medline]
-
Yuh WT, Zachar CK, Barloon TJ et al. Vertebral compression fractures: distinction between benign and malignant causes with MR imaging. Radiology 1989; 172(1):215-8.
[Medline]
-
Rupp RE, Ebraheim NA, Coombs RJ. Magnetic resonance imaging differentiation of compression spine fractures or vertebral lesions caused by osteoporosis or tumor. Spine 1995; 20(23):2499-503; discussion 2504.
[Medline]
-
Le Bihan D, Douek P, Argyropoulou M et al. Diffusion and perfusion magnetic resonance imaging in brain tumors. Top Magn Reson Imaging 1993; 5(1):25-31.
[Medline]
-
Bhugaloo AA, Abdullah BJJ, Siow YS et al. Diffusion weighted MR imaging in acute vertebral compression fractures: differentiation between malignant and benign causes. Biomed Imaging Interv J 2006; 2(2):e12.
[FREE
Full text]
[CrossRef]
-
The NOF Physicians Guide to Prevention and Treatment of Osteoporosis [Web Page]. Available at http://www.nof.org/osteoporosis/bmdtest.htm. (Accessed 10 May 2006).
[FREE
Full text]
-
Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med 2005; 353(2):164-71.
[Medline]
[CrossRef]
-
Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 1986; 314(26):1676-86.
[Medline]
-
McCarus DC. Fracture prevention in postmenopausal osteoporosis: a review of treatment options. Obstet Gynecol Surv 2006; 61(1):39-50.
[Medline]
[CrossRef]
-
Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338(11):736-46.
[Medline]
-
Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002; 288(18):2300-6.
[Medline]
-
Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med 1994; 330(6):387-92.
-
Chapter 15: Diseases of the connective tissues, joints and bones. in: Nuki G. Principles and Practice of Medicine. 931-3.
[Medline]
Received 26 August 2006; received in revised form 7 November 2006; accepted 8 November 2006
Correspondence: Department of Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. Tel.: +603-79492867; Fax: +603-21445944; E-mail: soraya@ummc.edu.my (Soraya Kunanayagam).
Please cite as: Kunanayagam S, Harichandra D, Sargunan S,
Low back pain, Biomed Imaging Interv J 2007; 3(4):e10
<URL: http://www.biij.org/2007/4/e10/>
This article has been viewed 17826 times.
|
|